Discovery of Selective Small-Molecule Ligands of SV2C by AI-Enhanced Virtual Screening and Experimental Validation
Published in BioRxiv, 2026
An virtual screening and experimental campaign that identified multiple novel chemotypes with low-micromolar affinity and marked selectivity for SV2C over SV2A and SV2B, yielding the first selective small-molecule ligands for this Parkinson’s disease target.
Recommended citation: Brueckner, Alexander C.; Martin, Matthew F.; Khuttan, Sheenam; Shields, Benjamin J.; Mittal, Anshumali; Schreiber, Jennifer A.; Salomon-Ferrer, Romelia; Bortolato, Andrea; Salahpour, Ali; Bucher, Meghan L.; Coleman, Jonathan A.; Miller, Gary W. "Discovery of Selective Small-Molecule Ligands of SV2C by AI-Enhanced Virtual Screening and Experimental Validation", BioRxiv, 2026. https://doi.org/10.64898/2026.08.11.744237
